参赭培气汤联合TACE治疗原发性肝癌的临床观察  

Clinical Effect of Shenzhe Peiqi Decoction Combined with TACE on Primary Liver Cancer

作　　者：贾磊 张跃强 曾祥学 JIA Lei;ZHANG Yue-qiang;ZENG Xiang-xue(Department of Oncology,Zhoukou Hospital of Traditional Chinese Medicine,Zhoukou Henan466000)

机构地区：[1]周口市中医院肿瘤科,河南周口466000

出　　处：《世界中西医结合杂志》2022年第3期584-588,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：河南省中医药科学研究专项课题(2016ZY3049)。

摘　　要：目的 观察参赭培气汤联合肝动脉化疗栓塞术(Tmnscatheter arterial chemoembolization, TACE)治疗原发性肝癌(Primary liver cancer, PLC)的临床疗效。方法 选取2017年6月—2020年6月期间周口市中医院肿瘤科收治的PLC患者100例,采用随机摸球法分为对照组和观察组,每组各50例。对照组单纯采用TACE治疗,在此基础上观察组加用参赭培气汤治疗。治疗6个疗程后,观察比较两组患者临床疗效、卡氏功能状态评分、不良反应发生率,同时比较两组患者治疗前后中医证候积分、肝功能参数[谷氨酸氨酸基转移酶(Alanine aminotransferase, ALT)、天冬氨酸氨基转移酶(Aspartate aminotransferase, AST)、总胆红素(Total bilirubin, TBIL)]、免疫功能指标[CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)]。结果 治疗后观察组有效率为46%(23/50)、疾病控制率为84%(42/50),对照组有效率为32%(16/50)、疾病控制率为72%(36/50),两组比较差异有统计学意义(P<0.05)。治疗后两组患者两肋胀痛、腹胀、嗳气纳差、乏力及纳呆积分均较治疗前明显降低,差异有统计学意义(P<0.05);且观察组中医证候积分均较对照组明显降低,差异有统计学意义(P<0.05)。治疗后两组患者血清TBIL、AST及ALT水平均较治疗前明显降低,差异有统计学意义(P<0.05);且观察组血清TBIL、AST及ALT水平均较对照组明显降低,差异有统计学意义(P<0.05)。治疗后两组患者免疫功能CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)指标均较治疗前升高,CD8^(+)指标均较治疗前降低,差异有统计学意义(P<0.05);且观察组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)均较对照组明显升高,CD8^(+)较对照组明显降低,差异有统计学意义(P<0.05)。治疗后两组患者KPS评分均较治疗前明显升高,差异有统计学意义(P<0.05);且观察组较对照组明显升高,差异有统计学意义(P<0.05)。治疗期间,对照组不良反应发生率为26.00%(13/50),观察组不良反应发生率为10.00%(5/50),两�Objective To investigate the clinical effect of Shenzhe Peiqi Decoction combined with transarterial chemoembolization(TACE)in the treatment of primary liver cancer(PLC).Methods A total of 100 PLC patients admitted to the Department of Oncology, Zhoukou Hospital of Traditional Chinese Medicine from June 2017 to June 2020 were randomly divided into a control group(50)and an observation group(50).The patients in the control group were treated with TACE alone, and those in the observation group received Shenzhe Peiqi Decoction on the basis of the treatment protocol of the control group.After six courses of treatment, the clinical efficacies, Karnofsky Performance Scale(KPS)scores, and incidence of adverse events were observed in both groups.The traditional Chinese medicine(TCM)syndrome scores, liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST),and total bilirubin(TBIL)],and immune function indicators[CD3^(+),CD4^(+),CD8^(+),and CD4^(+)/CD8^(+)]before and after treatment in the two groups were compared.Results The effective rate was 46%(23/50)and the disease control rate was 84%(42/50)in the observation group, higher than 32%(16/50)and 72%(36/50)of the control group, respectively(P<0.05).After treatment, the scores of swelling pain in bilateral ribs, abdominal distention, eructation, poor appetite, fatigue, and anorexia decreased in both groups(P<0.05),and the TCM syndrome scores in the observation group were lower than those in the control group(P<0.05).After treatment, the serum levels of TBIL,AST,and ALT in both groups decreased(P<0.05),and the above serum levels in the observation group were lower than those in thecontrol group(P<0.05).After treatment, CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)increased, while CD8^(+)decreased in both groups(P<0.05).Compared with the control after treatment, the observation group showed elevated CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)andreducedCD8^(+)(P<0.05).After treatment, the KPS scores in both groups increased(P<0.05),and the observation group was super

关 键 词：参赭培气汤 肝动脉化疗栓塞术 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]